Drug Profile
AR 13
Alternative Names: AR-13Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Arno Therapeutics
- Class Small molecules
- Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (PO)
- 24 Sep 2015 Antimicrobial data from a preclinical study in Cystic fibrosis released by Arno Therapeutics
- 01 Sep 2015 Preclinical trials in Cystic fibrosis in USA (unspecified route) before September 2015